Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares Sold by Baillie Gifford & Co.

Baillie Gifford & Co. lessened its holdings in shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP) by 29.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,819,095 shares of the biotechnology company’s stock after selling 4,956,765 shares during the quarter. Baillie Gifford & Co.’s holdings in Adaptimmune Therapeutics were worth $6,367,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of ADAP. Fullcircle Wealth LLC acquired a new position in shares of Adaptimmune Therapeutics in the 3rd quarter worth approximately $33,000. Vontobel Holding Ltd. grew its position in shares of Adaptimmune Therapeutics by 230.8% in the 3rd quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 30,000 shares in the last quarter. GSA Capital Partners LLP acquired a new position in shares of Adaptimmune Therapeutics in the 3rd quarter worth approximately $95,000. Virtu Financial LLC grew its position in shares of Adaptimmune Therapeutics by 27.5% in the 3rd quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company’s stock worth $96,000 after acquiring an additional 21,769 shares in the last quarter. Finally, Jane Street Group LLC grew its position in shares of Adaptimmune Therapeutics by 130.4% in the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock worth $166,000 after acquiring an additional 98,581 shares in the last quarter. Institutional investors and hedge funds own 31.37% of the company’s stock.

Adaptimmune Therapeutics Trading Up 0.9 %

NASDAQ:ADAP opened at $0.58 on Wednesday. The business has a 50 day simple moving average of $0.59 and a 200 day simple moving average of $0.80. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.82. The firm has a market capitalization of $149.18 million, a P/E ratio of -2.65 and a beta of 2.42. Adaptimmune Therapeutics plc has a 12-month low of $0.53 and a 12-month high of $2.05.

Wall Street Analyst Weigh In

ADAP has been the subject of several research reports. StockNews.com lowered Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 14th. Guggenheim reduced their price objective on Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, November 15th. HC Wainwright reduced their price objective on Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating for the company in a research report on Thursday, November 14th. Finally, Mizuho reduced their price objective on Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating for the company in a research report on Wednesday, November 27th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $2.79.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.